Pfizer points to drug shortages until mid-2024 as a result of tornado damage to North Carolina plant

Pfiz­er has restart­ed most of its man­u­fac­tur­ing lines that were im­pact­ed by tor­na­do dam­age ear­li­er this sum­mer at its fa­cil­i­ty in Rocky Mount, North Car­oli­na, but sup­ply in­ter­rup­tions for some med­i­cines may per­sist un­til mid-2024, the com­pa­ny said Mon­day.

Pfiz­er restart­ed pro­duc­tion of 13 med­i­cines made on lines im­pact­ed by the dam­age based on pa­tient need and in­ven­to­ry lev­els, the com­pa­ny said. As part of these ef­forts, Pfiz­er said it launched one line in the site’s new ster­ile in­jectable man­u­fac­tur­ing area, which the FDA ap­proved ear­li­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.